Curative Biotechnology Inc (CUBT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Curative Biotechnology Inc (CUBT) has a cash flow conversion efficiency ratio of 0.031x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-193.12K) by net assets ($-6.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CUBT net asset quality index to measure how much of total assets are equity-financed.
Curative Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Curative Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Curative Biotechnology Inc (CUBT) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Curative Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Curative Biotechnology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rockhopper Exploration
LSE:RKH
|
-0.004x |
|
Redsense Medical AB
ST:REDS
|
-0.053x |
|
DIGIDRIVE DISTRIBUTORS LTD
NSE:DIGIDRIVE
|
N/A |
|
Modern Internasional Tbk
JK:MDRN
|
0.057x |
|
Zaklady Urzadzen Kotlowych Staporkow SA
WAR:ZUK
|
0.028x |
|
Dongyang S.Tec Co.Ltd
KQ:060380
|
-0.075x |
|
Equity Story Group Ltd
AU:EQS
|
0.833x |
|
GENSOL ENGINEERING ORD (BSE)
NSE:GENSOL
|
0.068x |
Annual Cash Flow Conversion Efficiency for Curative Biotechnology Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Curative Biotechnology Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Curative Biotechnology Inc (CUBT) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-6.09 Million | $-868.87K | 0.143x | -31.43% |
| 2024-12-31 | $-4.91 Million | $-1.02 Million | 0.208x | +34.46% |
| 2023-12-31 | $-3.14 Million | $-486.58K | 0.155x | +107.00% |
| 2022-12-31 | $-20.53 Million | $-1.54 Million | 0.075x | -23.70% |
| 2021-12-31 | $-16.36 Million | $-1.60 Million | 0.098x | +133.19% |
| 2020-12-31 | $-4.52 Million | $-190.09K | 0.042x | +9914.88% |
| 2019-12-31 | $-357.33K | $-150.00 | 0.000x | +92.90% |
| 2018-12-31 | $-689.28K | $-150.00 | 0.000x | -4.34% |
| 2017-12-31 | $-659.37K | $-150.00 | 0.000x | -97.54% |
| 2016-12-31 | $-636.38K | $-5.89K | 0.009x | +393.09% |
| 2015-12-31 | $-618.98K | $1.96K | -0.003x | -111.64% |
| 2014-12-31 | $-773.80K | $-20.99K | 0.027x | -46.45% |
| 2013-12-31 | $-704.28K | $-35.68K | 0.051x | -- |
About Curative Biotechnology Inc
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying… Read more